Pneumonia, Viral

Infectious Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

MediciNova
MediciNovaLA JOLLA, CA
1 program
1
IbudilastPhase 21 trial
Active Trials
NCT04429555Completed34Est. Aug 2024
Providence Therapeutics
1 program
1
UNIKINONPhase 21 trial
Active Trials
NCT04344951TerminatedEst. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MediciNovaIbudilast
Providence TherapeuticsUNIKINON

Clinical Trials (2)

Total enrollment: 34 patients across 2 trials

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Start: Jan 2021Est. completion: Aug 202434 patients
Phase 2Completed

Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial

Start: Apr 2020Est. completion: Nov 2020
Phase 2Terminated

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space